BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanz-Garcia E, Zhao E, Bratman SV, Siu LL. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Sci Adv 2022;8:eabi8618. [PMID: 35080978 DOI: 10.1126/sciadv.abi8618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y, Wang Z, Yu Q, Liu X, Liu X, Dong S, Lv X, Bai Y, Wang S. Evaluating the performance of a plasma dual-target test developed based on sense-antisense and dual-MGB probe technique for colorectal cancer detection.. [DOI: 10.21203/rs.3.rs-2605730/v1] [Reference Citation Analysis]
2 Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med 2023. [PMID: 36928816 DOI: 10.1038/s41591-023-02226-6] [Reference Citation Analysis]
3 Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Fournier B, Dingemans AC, Dziadziuszko R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Ann Oncol 2023:S0923-7534(23)00089-3. [PMID: 36863484 DOI: 10.1016/j.annonc.2023.02.012] [Reference Citation Analysis]
4 Lin G, Li J. Circulating HPV DNA in HPV-associated cancers. Clin Chim Acta 2023;542:117269. [PMID: 36841427 DOI: 10.1016/j.cca.2023.117269] [Reference Citation Analysis]
5 Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW, Amir E. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. J Immunother Cancer 2023;11. [PMID: 36792122 DOI: 10.1136/jitc-2022-005854] [Reference Citation Analysis]
6 Koo KM. Multifunctional Hybrid Nanozymes for Magnetic Enrichment and Bioelectrocatalytic Sensing of Circulating Tumor RNA during Minimal Residual Disease Monitoring. Catalysts 2023;13:178. [DOI: 10.3390/catal13010178] [Reference Citation Analysis]
7 Li H, Luo Q, Zhang H, Ma X, Gu Z, Gong Q, Luo K. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chem Soc Rev 2023;52:47-96. [PMID: 36427082 DOI: 10.1039/d2cs00437b] [Reference Citation Analysis]
8 Telekes A, Horváth A. The Role of Cell-Free DNA in Cancer Treatment Decision Making. Cancers (Basel) 2022;14. [PMID: 36551600 DOI: 10.3390/cancers14246115] [Reference Citation Analysis]
9 Shah UJ, Alsulimani A, Ahmad F, Mathkor DM, Alsaieedi A, Harakeh S, Nasiruddin M, Haque S. Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. Biotechnol Genet Eng Rev 2022;38:339-83. [PMID: 35968863 DOI: 10.1080/02648725.2022.2108994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhao Y, Wang Z, Yu Q, Liu X, Liu X, Dong S, Lv X, Bai Y, Wang S. Robust performance of the methylated NTMT1 and MAP3K14-AS1 dual-target test for colorectal cancer detection in plasma by using sense-antisense and dual-MGB probe technique.. [DOI: 10.21203/rs.3.rs-1999722/v1] [Reference Citation Analysis]
11 Zhang L, Parvin R, Fan Q, Ye F. Emerging digital PCR technology in precision medicine. Biosensors and Bioelectronics 2022;211:114344. [DOI: 10.1016/j.bios.2022.114344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Mo H, Liu X, Xue Y, Chen H, Guo S, Li Z, Wang S, Li C, Han J, Fu M, Song Y, Li D, Ma F. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Mol Cancer 2022;21:171. [PMID: 36042494 DOI: 10.1186/s12943-022-01642-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Liang S, Li Y, Dong Q, Chen X. MMKP: A mind mapping knowledgebase prototyping tool for precision medicine. Front Immunol 2022;13:923528. [DOI: 10.3389/fimmu.2022.923528] [Reference Citation Analysis]
14 Saidak Z, Galmiche A, Ouendo M, Chatelain D, Constans J, Testelin S. Principe et applicabilité de la chirurgie de précision aux cancers de la tête et du cou. Med Sci (Paris) 2022;38:562-569. [DOI: 10.1051/medsci/2022082] [Reference Citation Analysis]
15 García-pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. [DOI: 10.1038/s41416-022-01776-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Yun KM, Cohen E, Department of Hematology-Oncology, Moores Cancer Center, UC San Diego Health, La Jolla, CA, USA, Department of Hematology-Oncology, Moores Cancer Center, UC San Diego Health, La Jolla, CA, USA. Clinical Utility of Human Papillomavirus Circulating Tumour DNA in Human Papillomavirus-positive Head and Neck Squamous Cell Carcinomas. Oncology & Haematology 2022;18:125. [DOI: 10.17925/ohr.2022.18.2.125] [Reference Citation Analysis]